IPP Bureau
Telangana targets Rs.1 lakh crore investments in Life Sciences by 2030
By IPP Bureau - October 27, 2025
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Syngene International expands capabilities with new bioconjugation suite in Bengaluru
By IPP Bureau - October 25, 2025
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Quest Diagnostics reports strong third quarter 2025 results and raises full-year guidance
By IPP Bureau - October 25, 2025
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study
By IPP Bureau - October 25, 2025
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors
By IPP Bureau - October 25, 2025
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Europe is putting vital medicines at risk by allowing ‘carbon heavy’ imports from the Far East: INEOS
By IPP Bureau - October 25, 2025
INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East
.jpg "Cipla to sell Lilly's weight-loss drug under new brand in India")
Cipla to sell Lilly's weight-loss drug under new brand in India
By IPP Bureau - October 24, 2025
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
AstraZeneca's imfinzi cuts death risk by 22% in early gastric cancer
By IPP Bureau - October 24, 2025
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Laurus Labs posts Q2 FY26 consolidated PAT higher at Rs. 195 Cr
By IPP Bureau - October 24, 2025
Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025
Caplin Steriles receives FDA approval for ANDA Nicardipine Hydrochloride in 0.9% Sodium Chloride injection
By IPP Bureau - October 24, 2025
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
IMCD showcases patient-centric pharmaceutical solutions at CPHI Frankfurt 2025
By IPP Bureau - October 24, 2025
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
Lupin launches authorized generic of Ravicti in US
By IPP Bureau - October 24, 2025
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Glenmark Pharmaceuticals USA to launch Ropivacaine Hydrochloride Injection USP
By IPP Bureau - October 23, 2025
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Moderna discontinues congenital virus program after Phase 3 trial fails to meet primary endpoint
By IPP Bureau - October 23, 2025
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Ipsen to acquire ImCheck Therapeutics to strengthen oncology pipeline
By IPP Bureau - October 23, 2025
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
